135 related articles for article (PubMed ID: 30888976)
1. Topical application of a dual PI3K/mTOR inhibitor prevents anal carcinogenesis in a human papillomavirus mouse model of anal cancer.
Rademacher BL; Matkowskyj KA; LaCount ED; Carchman EH
Eur J Cancer Prev; 2019 Nov; 28(6):483-491. PubMed ID: 30888976
[TBL] [Abstract][Full Text] [Related]
2. PI3K/mTOR inhibition prevents anal cancer in mice with established low-grade anal dysplasia.
Gunder LC; Moyer TH; Rademacher BL; Auyueng AS; Leverson G; Zhang W; Matkowskyj KA; Carchman EH
Exp Mol Pathol; 2022 Apr; 125():104752. PubMed ID: 35183509
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of Autophagy Contributes to Anal Carcinogenesis.
Carchman EH; Matkowskyj KA; Meske L; Lambert PF
PLoS One; 2016; 11(10):e0164273. PubMed ID: 27706233
[TBL] [Abstract][Full Text] [Related]
4. The role of pharmacologic modulation of autophagy on anal cancer development in an HPV mouse model of carcinogenesis.
Rademacher BL; Matkowskyj KA; Meske LM; Romero A; Sleiman H; Carchman EH
Virology; 2017 Jul; 507():82-88. PubMed ID: 28431282
[TBL] [Abstract][Full Text] [Related]
5. Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K/mTOR Inhibitors.
Gunder LC; Moyer TH; Johnson HR; Auyeung AS; Leverson GE; Zhang W; Matkowskyj KA; Carchman EH
J Surg Res; 2023 Feb; 282():137-146. PubMed ID: 36274448
[TBL] [Abstract][Full Text] [Related]
6. Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model.
Matsushima M; Kikuchi E; Matsumoto K; Hattori S; Takeda T; Kosaka T; Miyajima A; Oya M
Int J Oncol; 2015 Jul; 47(1):377-83. PubMed ID: 25963317
[TBL] [Abstract][Full Text] [Related]
7. Topical Protease Inhibitor Decreases Anal Carcinogenesis in a Transgenic Mouse Model of HPV Anal Disease.
Gunder LC; Johnson HR; Yao E; Moyer TH; Green HA; Sherer N; Zhang W; Carchman EH
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112993
[TBL] [Abstract][Full Text] [Related]
8. Systemic Delivery of a Dual PI3K/mTOR Inhibitor More Effective than Topical Delivery in Preventing Anal Carcinogenesis in an HPV Transgenic Mouse Model.
Gunder LC; Moyer TH; Ziolkowski MR; Keating MK; Leverson GE; Zhang W; Carchman EH
J Cancer Sci Clin Ther; 2022; 6(2):157-173. PubMed ID: 36683775
[TBL] [Abstract][Full Text] [Related]
9. PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer.
Chen L; Jin T; Zhu K; Piao Y; Quan T; Quan C; Lin Z
Oncotarget; 2017 Feb; 8(7):11937-11949. PubMed ID: 28060760
[TBL] [Abstract][Full Text] [Related]
10. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
Chang Z; Shi G; Jin J; Guo H; Guo X; Luo F; Song Y; Jia X
Int J Mol Med; 2013 Jun; 31(6):1449-56. PubMed ID: 23588698
[TBL] [Abstract][Full Text] [Related]
11. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
12. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
13. Effects of NVP-BEZ235 on the proliferation, migration, apoptosis and autophagy in HT-29 human colorectal adenocarcinoma cells.
Yu Y; Yu X; Ma J; Tong Y; Yao J
Int J Oncol; 2016 Jul; 49(1):285-93. PubMed ID: 27176231
[TBL] [Abstract][Full Text] [Related]
14. Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway.
Zhong JT; Yu J; Wang HJ; Shi Y; Zhao TS; He BX; Qiao B; Feng ZW
Tumour Biol; 2017 May; 39(5):1010428317697562. PubMed ID: 28459209
[TBL] [Abstract][Full Text] [Related]
15. Activating Mutations in
Shin MK; Payne S; Bilger A; Matkowskyj KA; Carchman E; Meyer DS; Bentires-Alj M; Deming DA; Lambert PF
Clin Cancer Res; 2019 Mar; 25(6):1889-1900. PubMed ID: 30530704
[TBL] [Abstract][Full Text] [Related]
16. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
17. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
[TBL] [Abstract][Full Text] [Related]
20. A Novel Model for Papillomavirus-Mediated Anal Disease and Cancer Using the Mouse Papillomavirus.
Blaine-Sauer S; Shin MK; Matkowskyj KA; Ward-Shaw E; Lambert PF
mBio; 2021 Aug; 12(4):e0161121. PubMed ID: 34281391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
